← Back to Search
Studies Of The HER-2/neu Proto-oncogene In Human Breast And Ovarian Cancer.
D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich
Published 1989 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.
This paper references
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
D. Zhou (1989)
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Alan L. Schechter (1984)
OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION
DeonJ. Venter (1987)
The molecular genetics of cellular oncogenes.
H. Varmus (1984)
Expression of cellular oncogenes in human malignancies.
D. Slamon (1984)
The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis.
S. Bacus (1988)
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor.
M. Press (1988)
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
Proto-oncogenes and human cancers.
D. Slamon (1987)
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
M. Berger (1988)
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
D. Zhou (1987)
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
W. Muller (1988)
Cellular oncogenes and retroviruses.
J. Bishop (1983)
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
C. Bargmann (1986)
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L. Coussens (1985)
The influence of protease digestion and duration of fixation on the immunostaining of keratins. A comparison of formalin and ethanol fixation.
H. Battifora (1986)
Amplification of c-erbB-2 and aggressive human breast tumors?
D. Slamon (1988)
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
C. Shih (1981)
An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin.
M. Press (1984)
Expression of p21 ras oncoproteins in human cancers.
T. Tanaka (1986)
Identification and characterization of the protein encoded by the human N-myc oncogene.
D. Slamon (1986)
Amplification and over-expression of the neu oncogene in human breast carcinomas.
M. J. van de Vijver (1988)
Estrogen and Progestin Binding in Cytosols of Ovarian Adenocarcinomas
J. A. Holt (1979)
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
D. Barnes (1988)
Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays.
M. Press (1985)
c-erbB-2 expression in benign and malignant breast disease.
B. Gusterson (1988)
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
J. Varley (1987)
Studies of the human c-myb gene and its product in human acute leukemias.
D. Slamon (1986)
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?
D. Slamon (1988)
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
C. Wright (1989)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
This paper is referenced by
Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis
S. Ramachandra (1990)
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.
R. Lupu (1990)
Gene amplification in gastric and esophageal adenocarcinomas.
J. Houldsworth (1990)
In situ distribution of transforming growth factor α in normal human tissues and in malignant tumours of the ovary
Friedrich Kommoss (1990)
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
A. Berchuck (1991)
Transformation and amplification of the K-fgf proto-oncogene in NIH-3T3 cells, and induction of metastatic potential.
J. Damen (1991)
Durchflußzytometrische DNA-Analyse bei Mammakarzinomen: Korrelation mit klinischen Prognosefaktoren
R. Kimmig (1991)
Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer
W. Muller (2004)
c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
M. Roux-Dosseto (1992)
The Role of HER‐2/neu Oncogene and Vimentin Filaments in the Production of the Paget's Phenotype
W. Hanna (2003)
Growth factors and oncogenes.
C. Ponzetto (1991)
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
B. Gusterson (1992)
Human Neuroblastoma: Paradigm for a Tumor with Oncogene Amplification and Loss of a Putative Tumor Suppressor Gene
E. Schwab (1992)
Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results.
P. V. van Diest (1992)
PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER
H. Kitagawa (1992)
Heterologous epidermal growth factor receptor (EGF-R) expression in larynx cancer cell lines: evidence for the existence of structurally modified receptors.
J. Bujía (1993)
Prognostic significance of the overexpression of c‐erbB‐2 protein in adenocarcinoma of the uterine cervix
T. Kihana (1994)
Salivary duct carcinoma—a highly aggressive salivary gland tumour with overexpression of c‐erB‐2
H. Hellquist (1994)
Genome scanning detects genetic alterations in human ovarian carcinoma
A. Magliocco (1994)
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2.
A. Forus (1993)
Protooncogenes in Endometriotic and Endometrial Tissue a
A. Bergqvist (1991)
Amplification, proto-oncogènes et cancers humains
P. Szepetowski (1991)
c‐erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast
A. Selim (2000)
Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis.
B. Brandt (1995)
Tumor Therapy by Immune Recruitment with Bispecific Antibodies
C. Renner (1995)
The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia.
H. Bühring (1995)
Gene Expression in Familial Breast Cancer: A Genetic-Epidemiologic Study of Premenopausal Bilateral Breast Cancer
R. Haile (1996)
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value.
J. K. Mellon (1996)
Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance.
K. Pantel (1996)
Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer.
P. Lipponen (1993)
Absence of Activating Mutations in the Transmembrane Domain of the c‐erbB‐2 Proto‐oncogene in Human Lung Cancer
R. Sachse (1992)
Quest for excellence: the ultimate goal of the radiation oncologist: ASTRO Gold Medal Address, 1992.
C. Perez (1993)See more